Chargement en cours...
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
Ivosidenib is an oral inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme, approved for treatment of IDH1-mutant (mIDH1) acute myeloid leukemia (AML). Preclinical work suggested that addition of azacitidine to ivosidenib enhances mIDH1 inhibition–related differentiation and apoptosis. P...
Enregistré dans:
| Publié dans: | J Clin Oncol |
|---|---|
| Auteurs principaux: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Society of Clinical Oncology
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7771719/ https://ncbi.nlm.nih.gov/pubmed/33119479 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01632 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|